Program
Fluconazole
Also written as “fluconazole”, “Fluconazole 400 mg” and “Diflucan®”.
Its studies are mostly in Meningitis, Cryptococcal · Candidiasis · Candidiasis, Oral · Candidemia · Lymphoma, led by 8 companies.
Drug pageFluconazole: every studyMany companies study it; this page follows only the 37 they lead. All 104 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 260 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Merckits history only | 30 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| AstraZenecaits history only | 20 open or running | phase 1since Mar 20, 2014 | Mar 20, 2014 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Jan 13, 2012 | Jan 13, 2012 | none ahead |
| Bayerits history only | 10 open or running | phase 1since Apr 17, 2019 | Apr 17, 2019 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | no phasesince Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Pharmtechnologyits history only | 10 open or running | phase 1since Jul 26, 2019 | Jul 26, 2019 | none ahead |
| Sutphin Drugsits history only | 10 open or running | early phase 1since Jul 31, 2020 | Jul 31, 2020 | none ahead |
Also a collaborator on its studies: Altasciences, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene and Vicuron Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 22 studies since Nov 2, 1999.
- Mar 11, 2003Phase 3 study in CandidiasisPfizer · NCT00056368 · 256 enrolled · United States
- Mar 25, 2008Phase 3 study in Tinea CapitisPfizer · NCT00645242 · 185 enrolled · United States, Puerto Rico
- May 29, 2008Phase 3 study in Candidiasis, InvasivePfizer · NCT00689338 · 216 enrolled · Austria, Belgium, Canada and more
- Dec 18, 2008Phase 3 study in LeukopeniaMerck · NCT00811928 · 252 enrolled
- Aug 3, 2010Phase 3 study in CandidemiaPfizer · NCT01176058 · 17 enrolled · China
- Jan 13, 2012Dr. Reddy's Laboratories’ first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01511770, NCT01511757
- Jan 28, 2013Phase 3 study in Candidiasis, VulvovaginalPfizer · NCT01806623 · 157 enrolled · Japan
- Mar 20, 2014AstraZeneca’s first study: phase 1 study in Solid TumoursNew to AstraZenecaAstraZeneca · NCT02093728 · 26 enrolled · United States
- Aug 20, 2014Phase 1 study in NeoplasmsPfizer · NCT02222922 · 138 enrolled · United States, Spain
- Aug 3, 2018Phase 1 study in BioequivalencePfizer · NCT03621072 · 36 enrolled · China
- Apr 17, 2019Bayer’s first study: phase 1 study in Pharmacology, ClinicalNew to BayerBayer · NCT03929861 · 26 enrolled · Germany
- Jul 26, 2019Pharmtechnology’s first study: phase 1 study in BioequivalenceNew to PharmtechnologyPharmtechnology · NCT04038008 · 26 enrolled · Canada
- Jul 31, 2020Sutphin Drugs’ first study: early phase 1 study in CandidiasisNew to Sutphin DrugsSutphin Drugs · NCT04502277 · 200 enrolled · United States, India
- Nov 17, 2021Phase 1 study in Healthy VolunteersAstraZeneca · NCT05140096 · 30 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Cytochrome P450 51 inhibitor”ChEMBL 37, by rule
Studies
All 37 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05140096Healthy Volunteers · United States | 1 | Completed | AstraZeneca | Apr 15, 2020 | 30 |
| NCT04502277Candidiasis · United States, India | Early 1 | UNKNOWN | Sutphin Drugs | Dec 31, 2020 | 200 |
| NCT04038008Bioequivalence · Canada | 1 | Completed | Pharmtechnology | Sep 17, 2019 | 26 |
| NCT03929861Pharmacology, Clinical · Germany | 1 | Completed | Bayer | Sep 10, 2012 | 26 |
| NCT03621072Bioequivalence · China | 1 | Completed | Pfizer | Jul 20, 2019 | 36 |
| NCT02222922Neoplasms · United States, Spain | 1 | Completed | Pfizer | Nov 5, 2019 | 138 |
| NCT02093728Solid Tumours · United States | 1 | Completed | AstraZeneca | Jun 2014 | 26 |
| NCT01806623Candidiasis, Vulvovaginal · Japan | 3 | Completed | Pfizer | Nov 22, 2013 | 157 |
| NCT01511770Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | Aug 2002 | 17 |
| NCT01511757Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | Jun 2002 | 15 |
| NCT01176058Candidemia · China | 3 | Terminated | Pfizer | Nov 2011 | 17 |
| NCT00811928Leukopenia | 3 | Completed | Merck | May 2010 | 252 |
| NCT00689338Candidiasis, Invasive · Austria, Belgium, Canada and more | 3 | Completed | Pfizer | May 2010 | 216 |
| NCT00645242Tinea Capitis · United States, Puerto Rico | 3 | Completed | Pfizer | 185 | |
| NCT00056368Candidiasis · United States | 3 | Completed | Pfizer | 256 | |
| NCT00002446Candidiasis, Oral · United States, Barbados | 3 | Completed | Merck | 300 | |
| NCT00002399Candidiasis, Oral · United States, Argentina, Belgium and more | 2 | Completed | Merck | 500 | |
| NCT00002339Candidiasis · United States | 3 | Completed | Pfizer | 100 | |
| NCT00002325Mycoses · United States | – | Completed | Pfizer | ||
| NCT00002306Meningitis, Cryptococcal · United States | – | Completed | Pfizer | ||
| NCT00002305Meningitis, Cryptococcal · United States, Canada | – | Completed | Pfizer | ||
| NCT00002304Candidiasis · United States, Canada | – | Completed | Pfizer | ||
| NCT00002294Meningitis, Cryptococcal · United States | – | Completed | Pfizer | ||
| NCT00002282Candidiasis, Oral · United States | – | Completed | Pfizer | ||
| NCT00002277Mycoses · United States | 3 | Completed | Pfizer | ||
| NCT00002132Candidiasis · United States | – | Completed | Johnson & Johnson | ||
| NCT00002113Meningitis, Cryptococcal · United States | – | Completed | Pfizer | 64 | |
| NCT00002112Candidiasis, Oral · United States | – | Completed | Pfizer | ||
| NCT00002077Meningitis, Cryptococcal · United States | – | Completed | Pfizer | ||
| NCT00002076Meningitis, Cryptococcal · United States | – | Completed | Pfizer | ||
| NCT00002075Meningitis, Cryptococcal · United States | – | Completed | Pfizer | ||
| NCT00002074Meningitis, Cryptococcal · United States, Canada | – | Completed | Pfizer | ||
| NCT00002068Meningitis, Cryptococcal · United States, Canada | – | Completed | Pfizer | ||
| NCT00002040Meningitis, Cryptococcal · United States | – | Completed | Pfizer | ||
| NCT00002038Candidiasis · United States | – | Completed | Pfizer | ||
| NCT00002010Meningitis · United States | – | Completed | Pfizer | ||
| NCT00001017Meningitis, Cryptococcal · United States | 3 | Completed | Pfizer | Jul 1991 | 330 |
How it is read
Names in the registry
- “Fluconazole”, 36 entries
- “fluconazole”, 5 entries
- “Fluconazole 400 mg”, 1 entry
- “Diflucan®”, 1 entry
- “Fluconazole 150mg Capsule Localized Originator”, 1 entry
Conditions, from the studies’ own filings
- Meningitis, Cryptococcal, 11 studies
- Candidiasis, 5 studies
- Candidiasis, Oral, 4 studies
- Candidemia, 3 studies
- Lymphoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.